Recombinant Antibodies Designed for Clearer In Vivo Results
RecombiMAb™ antibodies from Bio X Cell provide the foundation for consistent, reproducible performance across preclinical and translational research. These recombinant antibodies are designed to help control key variables that influence in vivo outcomes, including species compatibility, antibody format, and functional behavior.
By aligning antibody design with study requirements, RecombiMAb™ antibodies support clearer interpretation across in vivo and advanced in vitro organoid/organ-on-chip systems while maintaining continuity as programs evolve.
Browse Available Recombinant Antibodies
Sequence-defined recombinant antibodies built for consistent performance and continuity across preclinical workflows.
Recombinant Solutions for Program Continuity
Recombinant antibodies support consistent, reproducible performance across studies by enabling control over antibody format, species alignment, and functional behavior.
Bio X Cell Recombinant antibodies are commonly used to:
Deliver consistent, sequence-defined reagents across studies
Enable controlled engineering to align antibody format with study requirements
Support reproducibility and continuity as programs progress
These applications support work in in vivo systems and advanced in vitro organoid/organ-on-chip models.
New to recombinant antibodies?
Explore the fundamentals of recombinant antibody design and production →
Bio X Cell offers ready-to-use recombinant antibodies designed to provide immediate access to antibodies with consistent, reproducible performance for preclinical research. These antibodies offer a practical starting point for studies requiring consistency, format control, or species alignment.
Ready-to-use recombinant antibodies accelerate:
Entry into recombinant workflows without initiating a custom project
Access to defined antibody sequences suitable for preclinical use
Early exploration of format or species considerations within existing models
A clear pathway to custom engineering as study needs evolve
Many research programs begin with ready-to-use recombinant antibodies and move into custom engineering as study needs evolve.
| Approach | Best for | When teams use this approach |
|---|---|---|
| Ready-to-Use Recombinant Antibodies | Early studies or defined preclinical work | When sequence-defined reagents are needed with consistent format and species alignment, without custom development |
| Catalog-Based Customization | Studies needing defined adjustments | When targeted engineering is required to modify format, isotype, Fc, or species while maintaining reagent continuity |
| Fully Custom Recombinant Engineering | Program-specific or evolving requirements | When program-specific needs emerge requiring antibodies aligned to specific models, workflows, or long-term program goals |
Engineered Recombinant Antibodies Aligned to Your Study
When studies require greater control over antibody format, species, or functional properties, Bio X Cell supports recombinant antibody engineering using established expression systems and integrated production workflows.
Customization builds on recombinant foundations to maintain continuity while enabling deeper biological exploration.
| Engineering option | When it’s used | What it supports |
|---|---|---|
| Isotype, Fc, or format modification | When standard IgG formats are not appropriate for the study | Alignment of antibody structure and Fc activity with in vivo or mechanistic study needs |
| Species switching | When studies span different model systems | Continuity of target engagement across mouse, human, or other species |
| Sequence optimization | When expression, stability, or consistency must be refined | Reliable production of sequence-defined recombinant antibodies suitable for repeat use |
| Scale-up production | When material requirements increase | Consistent antibody supply as studies expand or programs progress |
| Product Name Link | Citation + Link |
|---|---|
| InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | Jarvi, N. L., Balu-Iyer, S. V., et al. (2023). A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics.. Commun Med (Lond). PubMed ID: 38066254 |
| InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | Iadonato, S., Ovechkina, Y., et al. (2023). A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.. Front Immunol. PubMed ID: 38152397 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Das, S., Valton, J., et al. (2023). Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.. Front Immunol. PubMed ID: 37251405 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Das, S., Valton, J., et al. (2023). Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. bioRxiv. |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Lam, W., Hu, R., et al. (2023). YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity.. Front Pharmacol. PubMed ID: 36686648 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Qiu, H., Zmina, P. M., et al. (2018). Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.. Cancer Lett. PubMed ID: 30036609 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Crupi, M. J. F., Taha, Z., et al. (2022). Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.. Front Immunol. PubMed ID: 36405739 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Qiu, H., Zmina, P. M., et al. (2018). Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.. Cancer Lett. PubMed ID: 30036609 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Jarvi, N. L., Balu-Iyer, S. V., et al. (2023). A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics.. Commun Med (Lond). PubMed ID: 38066254 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Lee, D., Dunn, Z. S., et al. (2023). Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering.. Nat Commun. PubMed ID: 37938576 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Sun, W., Wang, X., et al. (2022). CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer.. J Immunother Cancer. PubMed ID: 35851310 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Di Ianni, A., Fraone, T., et al. (2024). Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics.. Life Sci Alliance. PubMed ID: 37833075 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Wang, X., Su, S., et al. (2023). Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors.. Nat Commun. PubMed ID: 37723178 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Zheng, N., Fang, J., et al. (2022). Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance.. Cancer Cell. PubMed ID: 36027915 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Barbero, L., Ianni, A. D., et al. (2022). Assessing Major Histocompatibility Complex-Associated Peptide Proteomics assay as a tool to predict immunogenicity potential of protein therapeutics and antigens. Research Square. |
| InVivoSIM anti-human CD20 (Rituximab Biosimilar) | Jarvi, N. L., Balu-Iyer, S. V., et al. (2023). A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics.. Commun Med (Lond). PubMed ID: 38066254 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Liang, M., Sun, Z., et al. (2023). E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.. J Exp Clin Cancer Res. PubMed ID: 37865804 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Yu, W., He, J., et al. (2023). NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway.. Immunology. PubMed ID: 36420610 |
| InVivoSIM anti-human IL-17A (Secukinumab Biosimilar) | Wang, F., Li, Y., et al. (2024). Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.. Nat Commun. PubMed ID: 38172124 |
| InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | Wang, F., Zhou, F., et al. (2024). Macrophage Tim-3 maintains intestinal homeostasis in DSS-induced colitis by suppressing neutrophil necroptosis.. Redox Biol. PubMed ID: 38330550 |
| InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | Linde, I. L., Prestwood, T. R., et al. (2023). Neutrophil-activating therapy for the treatment of cancer.. Cancer Cell. PubMed ID: 36706760 |
| InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | Gupta, S., Pal, R., et al. (2024). Miniaturized Fab' imaging probe derived from a clinical antibody: Characterization and imaging in CRISPRi-attenuated mammary tumor models.. iScience. PubMed ID: 39184438 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Deng, R., Tian, R., et al. (2024). ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.. iScience. PubMed ID: 38591006 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Xiong, L., Tian, Y., et al. (2024). Immunopotentiating effects of herb-partitioned moxibustion on the spleens of cyclophosphamide-induced immunosuppressed rats.. Chin Med. PubMed ID: 38369521 |
| InVivoSIM anti-human CD20 (Rituximab Biosimilar) | Liu, S. J., Zou, C., et al. (2024). In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma.. Genome Biol. PubMed ID: 39375777 |
| InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | Deng, R., Tian, R., et al. (2024). ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.. iScience. PubMed ID: 38591006 |
| InVivoSIM anti-human CD20 (Rituximab Biosimilar) | Berjis, A., Muthumani, D., et al. (2024). Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation.. Nat Commun. PubMed ID: 38729924 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Rafiei, A., Gualandi, M., et al. (2024). IOS-1002, a Stabilized HLA-B57 Open Format, Exerts Potent Anti-Tumor Activity.. Cancers (Basel). PubMed ID: 39199672 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Sun, Y., Chen, Y., et al. (2024). ADCY4 promotes brain metastasis in small cell lung cancer and is associated with energy metabolism.. Heliyon. PubMed ID: 38596032 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Dong, H., He, X., et al. (2024). Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.. Nat Cancer. PubMed ID: 38413714 |
| InVivoSIM anti-human NGF (Tanezumab Biosimilar) | Hayes, B. W., Choi, H. W., et al. (2024). Recurrent infections drive persistent bladder dysfunction and pain via sensory nerve sprouting and mast cell activity.. Sci Immunol. PubMed ID: 38427717 |
| InVivoSIM anti-human NGF (Tanezumab Biosimilar) | Hayes, B. W., Choi, H. W., et al. (2024). Recurrent infections drive persistent bladder dysfunction and pain via sensory nerve sprouting and mast cell activity.. Science Immunology. |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Barcia Durán, J. G., Das, D., et al. (2024). Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.. Nat Cardiovasc Res. PubMed ID: 39613875 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Jensen, G., Wang, X., et al. (2024). Modeling immune checkpoint inhibitor associated myocarditis in vitro and its therapeutic implications.. J Mol Cell Cardiol Plus. PubMed ID: 39742339 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Yadav, S., Anbalagan, M., et al. (2025). Reactivation of CTLA4-expressing T cells accelerates resolution of lung fibrosis in a humanized mouse model.. J Clin Invest. PubMed ID: 40100323 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Søndergaard, J. N., Tulyeu, J., et al. (2025). Single cell suppression profiling of human regulatory T cells.. Nat Commun. PubMed ID: 39900891 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Barcia Durán, J. G., Das, D., et al. (2024). Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.. Nat Cardiovasc Res. PubMed ID: 39613875 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Jensen, G., Wang, X., et al. (2024). Modeling immune checkpoint inhibitor associated myocarditis in vitro and its therapeutic implications.. J Mol Cell Cardiol Plus. PubMed ID: 39742339 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Li, Y. J., Chien, S. H., et al. (2024). A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo.. Mol Ther. PubMed ID: 39091030 |
| InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | Huang, M., Lan, T., et al. (2025). Functional Role of NOXA in Hypoxia-Mediated PD-L1 Inhibitor Response in Hepatocellular Carcinoma.. Int J Mol Sci. PubMed ID: 40429910 |
| InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | Wang, Z., Yin, M., et al. (2025). Kynurenine promotes the immune escape of colorectal cancer cells via NAT10-mediated ac4C acetylation of PD-L1.. Clinics (Sao Paulo). PubMed ID: 40245789 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Zhao, Z., Hu, Y., et al. (2025). Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts.. J Immunother Cancer. PubMed ID: 40121032 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Jensen, G., Wang, X., et al. (2024). Modeling immune checkpoint inhibitor associated myocarditis in vitro and its therapeutic implications.. J Mol Cell Cardiol Plus. PubMed ID: 39742339 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | He, L., Zhang, X., et al. (2024). Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma.. Cell Rep Med. PubMed ID: 39303711 |
| InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) | Samplonius, D. F., van Wijngarden, A. P., et al. (2025). Enhancing the Anticancer Activity of a Carcinoma-Directed Peptide-HLA-I Fusion Protein by Armoring with Mutein IFNα.. Int J Mol Sci. PubMed ID: 40243928 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Dossou, A. S., Kang, S., et al. (2025). Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients.. Diagnostics (Basel). PubMed ID: 41095666 |
| InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | Zemp, F. J., Breckenridge, Z., et al. (2025). Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB. medRxiv. |
| InVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar) | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar) | Deng, S., Deng, R., et al. (2025). Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma.. iScience. PubMed ID: 40727936 |
| InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | Dossou, A. S., Kang, S., et al. (2025). Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients.. Diagnostics (Basel). PubMed ID: 41095666 |
| InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | Sun, Y., Maggs, L., et al. (2025). TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.. Cancer Immunol Res. PubMed ID: 39785827 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Søndergaard, J. N., Tulyeu, J., et al. (2025). Assessing Human Treg Suppression at Single-Cell Resolution Using Mass Cytometry.. Bio Protoc. PubMed ID: 40873476 |
| InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | Bortoleti, B. T. D. S., Quasem, S., et al. (2025). A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors.. Nat Commun. PubMed ID: 41219228 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Shi, Y. C., An, Q., et al. (2025). Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8+ T cell infiltration.. Oncoimmunology. PubMed ID: 40726089 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Deng, S., Deng, R., et al. (2025). Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma.. iScience. PubMed ID: 40727936 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Jeong, Y., Jang, H., et al. (2025). Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway.. Front Immunol. PubMed ID: 40308579 |
| InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar) | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Hsu, Y. P., Nourzaie, O., et al. (2023). Site-Specific Antibody Conjugation Using Modified Bisected N-Glycans: Method Development and Potential toward Tunable Effector Function.. Bioconjug Chem. PubMed ID: 37620302 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Liu, T., Zhang, M., et al. (2025). Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity.. Nat Commun. PubMed ID: 40595560 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Debinski, W., Fink, K. N., et al. (2025). Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate.. Breast Cancer Res. PubMed ID: 41146202 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Reitinger, C., Ipsen-Escobedo, A., et al. (2022). Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity.. Front Immunol. PubMed ID: 36248847 |
| RecombiMAb anti-mouse CTLA-4 (CD152) | Sun, T., Yang, Y., et al. (2024). High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis.. Parasit Vectors. PubMed ID: 39456030 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Myers Chen, K., Grun, D., et al. (2024). Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor.. Front Immunol. PubMed ID: 38726005 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Deng, R., Tian, R., et al. (2024). ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.. iScience. PubMed ID: 38591006 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Lepland, A., Peranzoni, E., et al. (2024). Therapeutic Tumor Macrophage Reprogramming in Breast Cancer Through a Peptide-Drug Conjugate. bioRxiv. |
| RecombiMAb anti-mouse PD-1 (CD279) | Gonçalves, M. P., Farah, R., et al. (2024). A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses.. iScience. PubMed ID: 38433914 |
| RecombiMAb mouse IgG2a isotype control, unknown specificity | Zhuang, Z., Zhou, J., et al. (2024). The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.. Cancers (Basel). PubMed ID: 38398223 |
| RecombiMAb anti-mouse PD-L1 (B7-H1) | Sun, T., Yang, Y., et al. (2024). High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis.. Parasit Vectors. PubMed ID: 39456030 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | He, L., Zhang, X., et al. (2024). Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma.. Cell Rep Med. PubMed ID: 39303711 |
| RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme | Yuan, X., Hao, X., et al. (2024). CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.. JCI Insight. PubMed ID: 39287984 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Maldonado, M. D. M., Gracia-Hernandez, M., et al. (2025). Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control.. J Immunother Cancer. PubMed ID: 40360436 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Lepland, A., Peranzoni, E., et al. (2025). Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer.. Adv Sci (Weinh). PubMed ID: 39840532 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Yuan, X., Hao, X., et al. (2024). CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.. JCI Insight. PubMed ID: 39287984 |
| RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) | Poppe, L. K., Roller, N., et al. (2025). Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy.. J Immunother Cancer. PubMed ID: 40316302 |
| RecombiMAb anti-mouse PD-1 (CD279) | Bikorimana, J. P., Farah, R., et al. (2025). Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.. iScience. PubMed ID: 40060894 |
| RecombiMAb anti-mouse PD-1 (CD279) | Liu, W. C., Wei, Y. H., et al. (2025). Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon response via MYC/CDK2/DNMT1 pathway.. Nat Commun. PubMed ID: 40461504 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Chen, K. M., Grun, D., et al. (2024). Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor. bioRxiv. |
| RecombiMAb anti-mouse CTLA-4 (CD152) | Blanchard, L., Vina, E., et al. (2025). Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade.. Cell Rep Med. PubMed ID: 40460830 |
| RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A) | Zhang, Y., Yu, S., et al. (2025). IL33-induced lipid droplet formation in mature low-density neutrophils drives colorectal cancer liver metastasis.. Cell Mol Immunol. PubMed ID: 41214328 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Cron, K. R., Fang, P., et al. (2025). ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response.. Oncotarget. PubMed ID: 41048107 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Levin, S., Benguigui, M., et al. (2025). Immature monocytic cells within tumors differentiate into immunosuppressive cells in resistant tumors to immunotherapy.. iScience. PubMed ID: 40822347 |
| RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme | Zemp, F. J., Breckenridge, Z., et al. (2025). Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB. medRxiv. |
| RecombiMAb human IgG1 isotype control, anti-respiratory syncytial virus | Ianniello, Z., Lu, H., et al. (2025). Harnessing ExDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach.. Mol Cancer. PubMed ID: 41077566 |
| RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme | Levin, S., Benguigui, M., et al. (2025). Immature monocytic cells within tumors differentiate into immunosuppressive cells in resistant tumors to immunotherapy.. iScience. PubMed ID: 40822347 |
| RecombiMAb anti-mouse PD-1 (CD279) | Shi, Y. C., An, Q., et al. (2025). Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8+ T cell infiltration.. Oncoimmunology. PubMed ID: 40726089 |
| RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme | Deng, S., Deng, R., et al. (2025). Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma.. iScience. PubMed ID: 40727936 |
How Fc Engineering Improves Mechanistic Clarity in In Vivo Studies
Fc behavior can significantly influence antibody performance in vivo.
Explore how Fc engineering strategies help reduce unintended immune effects and support clearer mechanistic interpretation across preclinical research workflows.
Mouse-Ready vs In Vivo-Ready Antibodies: Protecting Antibody Performance In Vivo
Unexpected variability in in vivo studies does not always originate from the biology itself. Explore how antibody formulation, endotoxin, aggregation, and reagent quality can influence mechanistic interpretation across preclinical workflows.
Recombinant antibodies support consistent, reproducible performance across studies by enabling control over antibody format, species alignment, and functional behavior.
Bio X Cell Recombinant antibodies are commonly used to:
Deliver consistent, sequence-defined reagents across studies
Enable controlled engineering to align antibody format with study requirements
Support reproducibility and continuity as programs progress
These applications support work in in vivo systems and advanced in vitro organoid/organ-on-chip models.
New to recombinant antibodies?
Explore the fundamentals of recombinant antibody design and production →
Bio X Cell offers ready-to-use recombinant antibodies designed to provide immediate access to antibodies with consistent, reproducible performance for preclinical research. These antibodies offer a practical starting point for studies requiring consistency, format control, or species alignment.
Ready-to-use recombinant antibodies accelerate:
Entry into recombinant workflows without initiating a custom project
Access to defined antibody sequences suitable for preclinical use
Early exploration of format or species considerations within existing models
A clear pathway to custom engineering as study needs evolve
Many research programs begin with ready-to-use recombinant antibodies and move into custom engineering as study needs evolve.
| Approach | Best for | When teams use this approach |
|---|---|---|
| Ready-to-Use Recombinant Antibodies | Early studies or defined preclinical work | When sequence-defined reagents are needed with consistent format and species alignment, without custom development |
| Catalog-Based Customization | Studies needing defined adjustments | When targeted engineering is required to modify format, isotype, Fc, or species while maintaining reagent continuity |
| Fully Custom Recombinant Engineering | Program-specific or evolving requirements | When program-specific needs emerge requiring antibodies aligned to specific models, workflows, or long-term program goals |
Engineered Recombinant Antibodies Aligned to Your Study
When studies require greater control over antibody format, species, or functional properties, Bio X Cell supports recombinant antibody engineering using established expression systems and integrated production workflows.
Customization builds on recombinant foundations to maintain continuity while enabling deeper biological exploration.
| Engineering option | When it’s used | What it supports |
|---|---|---|
| Isotype, Fc, or format modification | When standard IgG formats are not appropriate for the study | Alignment of antibody structure and Fc activity with in vivo or mechanistic study needs |
| Species switching | When studies span different model systems | Continuity of target engagement across mouse, human, or other species |
| Sequence optimization | When expression, stability, or consistency must be refined | Reliable production of sequence-defined recombinant antibodies suitable for repeat use |
| Scale-up production | When material requirements increase | Consistent antibody supply as studies expand or programs progress |
| Product Name Link | Citation + Link |
|---|---|
| InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | Jarvi, N. L., Balu-Iyer, S. V., et al. (2023). A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics.. Commun Med (Lond). PubMed ID: 38066254 |
| InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | Iadonato, S., Ovechkina, Y., et al. (2023). A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.. Front Immunol. PubMed ID: 38152397 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Das, S., Valton, J., et al. (2023). Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.. Front Immunol. PubMed ID: 37251405 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Das, S., Valton, J., et al. (2023). Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy. bioRxiv. |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Lam, W., Hu, R., et al. (2023). YIV-906 enhances nuclear factor of activated T-cells (NFAT) activity of T cells and promotes immune checkpoint blockade antibody action and CAR T-cell activity.. Front Pharmacol. PubMed ID: 36686648 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Qiu, H., Zmina, P. M., et al. (2018). Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.. Cancer Lett. PubMed ID: 30036609 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Crupi, M. J. F., Taha, Z., et al. (2022). Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.. Front Immunol. PubMed ID: 36405739 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Qiu, H., Zmina, P. M., et al. (2018). Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.. Cancer Lett. PubMed ID: 30036609 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Jarvi, N. L., Balu-Iyer, S. V., et al. (2023). A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics.. Commun Med (Lond). PubMed ID: 38066254 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Lee, D., Dunn, Z. S., et al. (2023). Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering.. Nat Commun. PubMed ID: 37938576 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Sun, W., Wang, X., et al. (2022). CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer.. J Immunother Cancer. PubMed ID: 35851310 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Di Ianni, A., Fraone, T., et al. (2024). Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics.. Life Sci Alliance. PubMed ID: 37833075 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Wang, X., Su, S., et al. (2023). Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors.. Nat Commun. PubMed ID: 37723178 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Zheng, N., Fang, J., et al. (2022). Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance.. Cancer Cell. PubMed ID: 36027915 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Barbero, L., Ianni, A. D., et al. (2022). Assessing Major Histocompatibility Complex-Associated Peptide Proteomics assay as a tool to predict immunogenicity potential of protein therapeutics and antigens. Research Square. |
| InVivoSIM anti-human CD20 (Rituximab Biosimilar) | Jarvi, N. L., Balu-Iyer, S. V., et al. (2023). A mechanistic marker-based screening tool to predict clinical immunogenicity of biologics.. Commun Med (Lond). PubMed ID: 38066254 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Liang, M., Sun, Z., et al. (2023). E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.. J Exp Clin Cancer Res. PubMed ID: 37865804 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Yu, W., He, J., et al. (2023). NR4A1 mediates NK-cell dysfunction in hepatocellular carcinoma via the IFN-γ/p-STAT1/IRF1 pathway.. Immunology. PubMed ID: 36420610 |
| InVivoSIM anti-human IL-17A (Secukinumab Biosimilar) | Wang, F., Li, Y., et al. (2024). Targeting IL-17A enhances imatinib efficacy in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia.. Nat Commun. PubMed ID: 38172124 |
| InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | Wang, F., Zhou, F., et al. (2024). Macrophage Tim-3 maintains intestinal homeostasis in DSS-induced colitis by suppressing neutrophil necroptosis.. Redox Biol. PubMed ID: 38330550 |
| InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | Linde, I. L., Prestwood, T. R., et al. (2023). Neutrophil-activating therapy for the treatment of cancer.. Cancer Cell. PubMed ID: 36706760 |
| InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | Gupta, S., Pal, R., et al. (2024). Miniaturized Fab' imaging probe derived from a clinical antibody: Characterization and imaging in CRISPRi-attenuated mammary tumor models.. iScience. PubMed ID: 39184438 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Deng, R., Tian, R., et al. (2024). ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.. iScience. PubMed ID: 38591006 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Xiong, L., Tian, Y., et al. (2024). Immunopotentiating effects of herb-partitioned moxibustion on the spleens of cyclophosphamide-induced immunosuppressed rats.. Chin Med. PubMed ID: 38369521 |
| InVivoSIM anti-human CD20 (Rituximab Biosimilar) | Liu, S. J., Zou, C., et al. (2024). In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastoma.. Genome Biol. PubMed ID: 39375777 |
| InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | Deng, R., Tian, R., et al. (2024). ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.. iScience. PubMed ID: 38591006 |
| InVivoSIM anti-human CD20 (Rituximab Biosimilar) | Berjis, A., Muthumani, D., et al. (2024). Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation.. Nat Commun. PubMed ID: 38729924 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Rafiei, A., Gualandi, M., et al. (2024). IOS-1002, a Stabilized HLA-B57 Open Format, Exerts Potent Anti-Tumor Activity.. Cancers (Basel). PubMed ID: 39199672 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Sun, Y., Chen, Y., et al. (2024). ADCY4 promotes brain metastasis in small cell lung cancer and is associated with energy metabolism.. Heliyon. PubMed ID: 38596032 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Dong, H., He, X., et al. (2024). Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.. Nat Cancer. PubMed ID: 38413714 |
| InVivoSIM anti-human NGF (Tanezumab Biosimilar) | Hayes, B. W., Choi, H. W., et al. (2024). Recurrent infections drive persistent bladder dysfunction and pain via sensory nerve sprouting and mast cell activity.. Sci Immunol. PubMed ID: 38427717 |
| InVivoSIM anti-human NGF (Tanezumab Biosimilar) | Hayes, B. W., Choi, H. W., et al. (2024). Recurrent infections drive persistent bladder dysfunction and pain via sensory nerve sprouting and mast cell activity.. Science Immunology. |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Barcia Durán, J. G., Das, D., et al. (2024). Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.. Nat Cardiovasc Res. PubMed ID: 39613875 |
| InVivoSIM anti-human PD-1 (Nivolumab Biosimilar) | Jensen, G., Wang, X., et al. (2024). Modeling immune checkpoint inhibitor associated myocarditis in vitro and its therapeutic implications.. J Mol Cell Cardiol Plus. PubMed ID: 39742339 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Yadav, S., Anbalagan, M., et al. (2025). Reactivation of CTLA4-expressing T cells accelerates resolution of lung fibrosis in a humanized mouse model.. J Clin Invest. PubMed ID: 40100323 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Søndergaard, J. N., Tulyeu, J., et al. (2025). Single cell suppression profiling of human regulatory T cells.. Nat Commun. PubMed ID: 39900891 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Barcia Durán, J. G., Das, D., et al. (2024). Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.. Nat Cardiovasc Res. PubMed ID: 39613875 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Jensen, G., Wang, X., et al. (2024). Modeling immune checkpoint inhibitor associated myocarditis in vitro and its therapeutic implications.. J Mol Cell Cardiol Plus. PubMed ID: 39742339 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Li, Y. J., Chien, S. H., et al. (2024). A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo.. Mol Ther. PubMed ID: 39091030 |
| InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | Huang, M., Lan, T., et al. (2025). Functional Role of NOXA in Hypoxia-Mediated PD-L1 Inhibitor Response in Hepatocellular Carcinoma.. Int J Mol Sci. PubMed ID: 40429910 |
| InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | Wang, Z., Yin, M., et al. (2025). Kynurenine promotes the immune escape of colorectal cancer cells via NAT10-mediated ac4C acetylation of PD-L1.. Clinics (Sao Paulo). PubMed ID: 40245789 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Zhao, Z., Hu, Y., et al. (2025). Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts.. J Immunother Cancer. PubMed ID: 40121032 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Jensen, G., Wang, X., et al. (2024). Modeling immune checkpoint inhibitor associated myocarditis in vitro and its therapeutic implications.. J Mol Cell Cardiol Plus. PubMed ID: 39742339 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | He, L., Zhang, X., et al. (2024). Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma.. Cell Rep Med. PubMed ID: 39303711 |
| InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) | Samplonius, D. F., van Wijngarden, A. P., et al. (2025). Enhancing the Anticancer Activity of a Carcinoma-Directed Peptide-HLA-I Fusion Protein by Armoring with Mutein IFNα.. Int J Mol Sci. PubMed ID: 40243928 |
| InVivoSIM anti-human TNFα (Infliximab Biosimilar) | Dossou, A. S., Kang, S., et al. (2025). Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients.. Diagnostics (Basel). PubMed ID: 41095666 |
| InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) | Zemp, F. J., Breckenridge, Z., et al. (2025). Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB. medRxiv. |
| InVivoSIM anti-human IL-12 p40 (Ustekinumab Biosimilar) | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar) | Deng, S., Deng, R., et al. (2025). Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma.. iScience. PubMed ID: 40727936 |
| InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | Dossou, A. S., Kang, S., et al. (2025). Validation of the i-Tracker Drug and Total Anti-Drug Antibody CLIA Assays on IDS-iSYS for Therapeutic Drug Monitoring in Adalimumab- and Infliximab-Treated Patients.. Diagnostics (Basel). PubMed ID: 41095666 |
| InVivoSIM anti-human TNFα (Adalimumab Biosimilar) | Sun, Y., Maggs, L., et al. (2025). TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids.. Cancer Immunol Res. PubMed ID: 39785827 |
| InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar) | Søndergaard, J. N., Tulyeu, J., et al. (2025). Assessing Human Treg Suppression at Single-Cell Resolution Using Mass Cytometry.. Bio Protoc. PubMed ID: 40873476 |
| InVivoSIM anti-human EGFR (Cetuximab Biosimilar) | Bortoleti, B. T. D. S., Quasem, S., et al. (2025). A monoclonal antibody that inhibits the shedding of CD16a and CD16b and promotes antibody-dependent cellular cytotoxicity against tumors.. Nat Commun. PubMed ID: 41219228 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Shi, Y. C., An, Q., et al. (2025). Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8+ T cell infiltration.. Oncoimmunology. PubMed ID: 40726089 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Deng, S., Deng, R., et al. (2025). Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma.. iScience. PubMed ID: 40727936 |
| InVivoSIM anti-human PD-1 (Pembrolizumab Biosimilar) | Jeong, Y., Jang, H., et al. (2025). Dual targeting of EZH2 and PD-L1 in Burkitt's lymphoma enhances immune activation and induces apoptotic pathway.. Front Immunol. PubMed ID: 40308579 |
| InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar) | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Hsu, Y. P., Nourzaie, O., et al. (2023). Site-Specific Antibody Conjugation Using Modified Bisected N-Glycans: Method Development and Potential toward Tunable Effector Function.. Bioconjug Chem. PubMed ID: 37620302 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Liu, T., Zhang, M., et al. (2025). Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity.. Nat Commun. PubMed ID: 40595560 |
| InVivoSIM anti-human HER2 (Trastuzumab Biosimilar) | Debinski, W., Fink, K. N., et al. (2025). Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate.. Breast Cancer Res. PubMed ID: 41146202 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Reitinger, C., Ipsen-Escobedo, A., et al. (2022). Modulation of urelumab glycosylation separates immune stimulatory activity from organ toxicity.. Front Immunol. PubMed ID: 36248847 |
| RecombiMAb anti-mouse CTLA-4 (CD152) | Sun, T., Yang, Y., et al. (2024). High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis.. Parasit Vectors. PubMed ID: 39456030 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Myers Chen, K., Grun, D., et al. (2024). Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor.. Front Immunol. PubMed ID: 38726005 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Deng, R., Tian, R., et al. (2024). ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.. iScience. PubMed ID: 38591006 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Lepland, A., Peranzoni, E., et al. (2024). Therapeutic Tumor Macrophage Reprogramming in Breast Cancer Through a Peptide-Drug Conjugate. bioRxiv. |
| RecombiMAb anti-mouse PD-1 (CD279) | Gonçalves, M. P., Farah, R., et al. (2024). A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses.. iScience. PubMed ID: 38433914 |
| RecombiMAb mouse IgG2a isotype control, unknown specificity | Zhuang, Z., Zhou, J., et al. (2024). The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.. Cancers (Basel). PubMed ID: 38398223 |
| RecombiMAb anti-mouse PD-L1 (B7-H1) | Sun, T., Yang, Y., et al. (2024). High PD-1 and CTLA-4 expression correlates with host immune suppression in patients and a mouse model infected with Echinococcus multilocularis.. Parasit Vectors. PubMed ID: 39456030 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | He, L., Zhang, X., et al. (2024). Reprograming immunosuppressive microenvironment by eIF4G1 targeting to eradicate pancreatic ductal adenocarcinoma.. Cell Rep Med. PubMed ID: 39303711 |
| RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme | Yuan, X., Hao, X., et al. (2024). CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.. JCI Insight. PubMed ID: 39287984 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Maldonado, M. D. M., Gracia-Hernandez, M., et al. (2025). Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control.. J Immunother Cancer. PubMed ID: 40360436 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Lepland, A., Peranzoni, E., et al. (2025). Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer.. Adv Sci (Weinh). PubMed ID: 39840532 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Yuan, X., Hao, X., et al. (2024). CREB-binding protein/P300 bromodomain inhibition reduces neutrophil accumulation and activates antitumor immunity in triple-negative breast cancer.. JCI Insight. PubMed ID: 39287984 |
| RecombiMAb anti-mouse PD-1 (CD279) (LALA-PG) | Poppe, L. K., Roller, N., et al. (2025). Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy.. J Immunother Cancer. PubMed ID: 40316302 |
| RecombiMAb anti-mouse PD-1 (CD279) | Bikorimana, J. P., Farah, R., et al. (2025). Forced intracellular degradation of xenoantigens as a modality for cell-based cancer immunotherapy.. iScience. PubMed ID: 40060894 |
| RecombiMAb anti-mouse PD-1 (CD279) | Liu, W. C., Wei, Y. H., et al. (2025). Inhibition of tumor-intrinsic NAT10 enhances antitumor immunity by triggering type I interferon response via MYC/CDK2/DNMT1 pathway.. Nat Commun. PubMed ID: 40461504 |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Chen, K. M., Grun, D., et al. (2024). Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor. bioRxiv. |
| RecombiMAb anti-mouse CTLA-4 (CD152) | Blanchard, L., Vina, E., et al. (2025). Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade.. Cell Rep Med. PubMed ID: 40460830 |
| RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A) | Zhang, Y., Yu, S., et al. (2025). IL33-induced lipid droplet formation in mature low-density neutrophils drives colorectal cancer liver metastasis.. Cell Mol Immunol. PubMed ID: 41214328 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Cron, K. R., Fang, P., et al. (2025). ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response.. Oncotarget. PubMed ID: 41048107 |
| RecombiMAb anti-mouse PD-1 (CD279) (D265A) | Levin, S., Benguigui, M., et al. (2025). Immature monocytic cells within tumors differentiate into immunosuppressive cells in resistant tumors to immunotherapy.. iScience. PubMed ID: 40822347 |
| RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme | Zemp, F. J., Breckenridge, Z., et al. (2025). Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB. medRxiv. |
| RecombiMAb human IgG1 isotype control, anti-respiratory syncytial virus | Ianniello, Z., Lu, H., et al. (2025). Harnessing ExDNA for precision exatecan delivery in cancer: a novel antibody-drug conjugate approach.. Mol Cancer. PubMed ID: 41077566 |
| RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| RecombiMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme | Zhu, X., Yu, Y., et al. (2025). Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies. medRxiv. |
| RecombiMAb mouse IgG2a (D265A) isotype control, anti-hen egg lysozyme | Levin, S., Benguigui, M., et al. (2025). Immature monocytic cells within tumors differentiate into immunosuppressive cells in resistant tumors to immunotherapy.. iScience. PubMed ID: 40822347 |
| RecombiMAb anti-mouse PD-1 (CD279) | Shi, Y. C., An, Q., et al. (2025). Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8+ T cell infiltration.. Oncoimmunology. PubMed ID: 40726089 |
| RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme | Deng, S., Deng, R., et al. (2025). Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma.. iScience. PubMed ID: 40727936 |
How Fc Engineering Improves Mechanistic Clarity in In Vivo Studies
Fc behavior can significantly influence antibody performance in vivo.
Explore how Fc engineering strategies help reduce unintended immune effects and support clearer mechanistic interpretation across preclinical research workflows.
Mouse-Ready vs In Vivo-Ready Antibodies: Protecting Antibody Performance In Vivo
Unexpected variability in in vivo studies does not always originate from the biology itself. Explore how antibody formulation, endotoxin, aggregation, and reagent quality can influence mechanistic interpretation across preclinical workflows.
Custom Antibody Services
Antibody Engineering
Start Your Project
Don’t see what you need?
Consult With Bio X Cell to Enable Your Next Breakthrough Discovery
Whether you need antibody customization or high-volume production, Bio X Cell is committed to advancing your therapeutic innovations.
Contact Us